Mail

SOLTF - Sosei Group Corporation

Other OTC - Other OTC Delayed Price. Currency in USD

Sosei Group Corporation

PMO Hanzomon
11th Floor 2-1 Kojimachi Chiyoda-ku
Tokyo 102-0083
Japan
81 3 5210 3290
https://soseiheptares.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 202

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Shinichi Tamura	Founder & Chairman	2.36M	N/A	1949
Mr. Chris Cargill	Representative Exec. Officer, Pres, CEO & Director	1.66M	N/A	1984
Mr. Hironoshin Nomura	Sr. VP of Investor Relations, VP & Corp. Strategy, Exec. Officer and CFO	N/A	N/A	N/A
Mr. Kieran Johnson F.C.A.	Exec. Officer, VP & Chief Accounting Officer	N/A	N/A	N/A
Dr. Miles Congreve	Chief Scientific Officer	N/A	N/A	N/A
Mr. Kazuhiko Yoshizumi	Exec. Officer, VP & Chief Compliance Officer	N/A	N/A	1954
Shinichiro Nishishita	VP of Investor Relations & Head of Regulatory Disclosures	N/A	N/A	N/A
Stacey Southall	Associate Director & Head of Biophysics	N/A	N/A	N/A
Ms. Candelle Chong	Exec. Officer, Exec. VP & Chief of Staff	N/A	N/A	N/A
Dr. Matt Barnes	Head of Drug Discovery, Exec. Officer, VP, Pres of Heptares Therapeutics Ltd. & Head of UK R&D	N/A	N/A	N/A

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Sosei Group Corporation develops biopharmaceutical products worldwide. Its marketed products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair to treat asthma; and ORAVI, an oropharyngeal candidiasis. The company's product pipeline consists of GPR35 agonist, for inflammatory bowel disease/GI disorders, which is in preclinical stage; HTL0016878 for Schizophrenia and other neuropsychiatric disorders; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; and PF-07258669 for anorexia. Sosei Group Corporation has a strategic collaboration with AbbVie, Biohaven, Genentech, GSK, Takeda, Pfizer, Neurocrine Biosciences, Novartis, Verily, AstraZeneca, and Takeda. The company was incorporated in 1990 and is headquartered in Tokyo, Japan.

Corporate Governance

Sosei Group Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.